168 related articles for article (PubMed ID: 37702218)
1. ICH S7B In Vitro Assays Do Not Address Mechanisms of QT
Wu WW; Choe M; Johannesen L; Vicente J; Bende G; Stockbridge NL; Strauss DG; Garnett C
Clin Pharmacol Ther; 2023 Dec; 114(6):1332-1341. PubMed ID: 37702218
[TBL] [Abstract][Full Text] [Related]
2. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
[TBL] [Abstract][Full Text] [Related]
3. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
[TBL] [Abstract][Full Text] [Related]
4. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development.
Redfern WS; Carlsson L; Davis AS; Lynch WG; MacKenzie I; Palethorpe S; Siegl PK; Strang I; Sullivan AT; Wallis R; Camm AJ; Hammond TG
Cardiovasc Res; 2003 Apr; 58(1):32-45. PubMed ID: 12667944
[TBL] [Abstract][Full Text] [Related]
5. Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium.
Park E; Gintant GA; Bi D; Kozeli D; Pettit SD; Pierson JB; Skinner M; Willard J; Wisialowski T; Koerner J; Valentin JP
Br J Pharmacol; 2018 Feb; 175(4):606-617. PubMed ID: 29181850
[TBL] [Abstract][Full Text] [Related]
6. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
[TBL] [Abstract][Full Text] [Related]
7. Drug-induced QT prolongation: Concordance of preclinical anesthetized canine model in relation to published clinical observations for ten CiPA drugs.
Koshman YE; Wilsey AS; Bird BM; Endemann AL; Sadilek S; Treadway J; Martin RL; Polakowski JS; Gintant GA; Mittelstadt SW
J Pharmacol Toxicol Methods; 2020; 103():106871. PubMed ID: 32360993
[TBL] [Abstract][Full Text] [Related]
8. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
9. The Challenges of Predicting Drug-Induced QTc Prolongation in Humans.
Valentin JP; Hoffmann P; Ortemann-Renon C; Koerner J; Pierson J; Gintant G; Willard J; Garnett C; Skinner M; Vargas HM; Wisialowski T; Pugsley MK
Toxicol Sci; 2022 Apr; 187(1):3-24. PubMed ID: 35148401
[TBL] [Abstract][Full Text] [Related]
10. Revisiting the hERG safety margin after 20 years of routine hERG screening.
Leishman DJ; Abernathy MM; Wang EB
J Pharmacol Toxicol Methods; 2020 Sep; 105():106900. PubMed ID: 32768644
[TBL] [Abstract][Full Text] [Related]
11. Determination of five positive control drugs in hERG external solution (buffer) by LC-MS/MS to support in vitro hERG assay as recommended by ICH S7B.
King TI; Indapurkar A; Tariq I; DePalma R; Mistry S; Alvarez-Baron C; Ismaiel OA; Wu W; Chiu K; Patel V; Rouse R; Strauss DG; Matta MK
J Pharmacol Toxicol Methods; 2022; 118():107229. PubMed ID: 36334898
[TBL] [Abstract][Full Text] [Related]
12. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute.
Vargas HM; Rossman EI; Wisialowski TA; Nichols J; Pugsley MK; Roche B; Gintant GA; Greiter-Wilke A; Kleiman RB; Valentin JP; Leishman DJ
J Pharmacol Toxicol Methods; 2023; 121():107265. PubMed ID: 36997076
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation.
Gintant G
Pharmacol Ther; 2011 Feb; 129(2):109-19. PubMed ID: 20807552
[TBL] [Abstract][Full Text] [Related]
14. Non-clinical evaluation of ventricular repolarization (ICH S7B): results of an interim survey of international pharmaceutical companies.
Friedrichs GS; Patmore L; Bass A
J Pharmacol Toxicol Methods; 2005; 52(1):6-11. PubMed ID: 15975833
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical proarrhythmia models: predicting Torsades de Pointes.
Lawrence CL; Pollard CE; Hammond TG; Valentin JP
J Pharmacol Toxicol Methods; 2005; 52(1):46-59. PubMed ID: 15975832
[TBL] [Abstract][Full Text] [Related]
16. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
17. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B/E14 Studies Needed for Low-Risk Modalities?
Qu Y; Henderson KA; Harper TA; Vargas HM
Clin Pharmacol Ther; 2024 Jul; 116(1):96-105. PubMed ID: 38362953
[TBL] [Abstract][Full Text] [Related]
18. Testing the nonclinical Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm with an established anti-seizure medication: Levetiracetam case study.
Delaunois A; Mathy FX; Cornet M; Gryshkova V; Korlowski C; Bonfitto F; Koch J; Schlit AF; Hebeisen S; Passini E; Rodriguez B; Valentin JP
Pharmacol Res Perspect; 2023 Feb; 11(1):e01059. PubMed ID: 36748725
[TBL] [Abstract][Full Text] [Related]
19. Electrocardiographic biomarkers to confirm drug's electrophysiological effects used for proarrhythmic risk prediction under CiPA.
Vicente J; Hosseini M; Johannesen L; Strauss DG
J Electrocardiol; 2017; 50(6):808-813. PubMed ID: 28928044
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of QT prolongation by buprenorphine cannot be explained by direct hERG channel block.
Tran PN; Sheng J; Randolph AL; Baron CA; Thiebaud N; Ren M; Wu M; Johannesen L; Volpe DA; Patel D; Blinova K; Strauss DG; Wu WW
PLoS One; 2020; 15(11):e0241362. PubMed ID: 33157550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
